Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS207 +/- JS015 + XELOX in Advanced Colorectal Cancer
NCT06885385Phase 2Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of JS207 in colorectal cancer (CRC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Apr 2025; status: recruiting.
02
Drugs
JS207
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06885385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06885385.